A single‐center prospective clinical trial (NCT02560519) was recently published by Pesonen et al., and found no significant difference in adverse events, including arrhythmias (defined as ventricular arrhythmias, POAF, or need for a permanent pacemaker) with use of albumin compared to ringer acetate after cardiac surgery.24 This evidence concerns the gene ALB and cardiac arrhythmia.